Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Completed · Phase 3

Conditions studied: Pediatric Growth Hormone Deficiency

In brief

This is an open-label, randomized, multicenter, efficacy and safety study of weekly MOD-4023 compared to daily Genotropin therapy in pre-pubertal children with growth hormone deficiency.

Key facts

Study ID
NCT02968004
Run by
OPKO Health, Inc.
People needed
224
Starts
2016-12-01
Expected to finish
2024-05-01
Last updated by the study team
2025-07-20

Who can join

Age: 3 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.